Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actinic Keratosis
New actinic keratosis study findings have been published by L. Anderson and colleagues
July 13th, 2009
"There is a need for improved medical approaches to the treatment of actinic keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus, is being evaluated as a topical therapy for actinic keratosis," investigators in the United States report. "Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 closing regimens for the treatment of actinic keratosis. Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-tip period. All 3 active treatments were significantly more effective...
Source: Biotech Business Week (2009-07-13)
|
